Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2013

View Archived Issues

The identification of an accessory protein that plays a role in mammalian obesity

Astex Pharmaceuticals reports topline results from phase II SGI-110 trial

New monoclonal antibodies disclosed as modulators of CD324

The role of B7-H6/NKp30 axis in the pathogenesis of primary Sjogren's syndrome

NAPOLI-1 liposomal irinotecan trial reaches enrollment goal

Clovis begins dosing with new formulation of CO-1686

Daewoong presents bioequivalence data for rosuvastatin/olmesartan fixed-dose formulation

FDA accepts ibrutinib NDA filing for review

Epirus Biopharmaceuticals reports phase III data on biosimilar infliximab product

Isis Pharmaceuticals begins phase II diabetes study

Constellation Pharmaceuticals discloses novel EZH2 inhibitors

Researchers at Orbsen Therapeutics design novel stromal stem cells

Dezima Pharma begins phase IIb TULIP trial for DEZ-001

Idera Pharmaceuticals and NCI enter M-CRADA agreement

AbbVie initiates second pivotal study of elagolix for endometriosis

Improved control of recurrent UTIs with quorum sensing inhibitor LED-209

FDA issues tolvaptan CRL for kidney disease

Stivarga approved in E.U. for metastatic colorectal cancer

OPKO Health completes acquisition of Prolor Biotech

Novel HDAC inhibitor shows potent antiproliferative activity in vivo

Researchers disclose new agents for the diagnosis of cancer and gastrointestinal disorders

French team synthesizes new antibacterial agents

Scientists at Daiichi Sankyo patent new sodium channel blockers

Zealand and Lilly to collaborate on first-in-class peptide therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...